Skip to main content
Gujarat Themis Biosyn Ltd. logo

Gujarat Themis Biosyn Ltd. — Investor Relations & Filings

Ticker · GUJTHEM ISIN · INE942C01045 LEI · 3358009IT99XRO254Q79 BSE.NS Manufacturing
Open in API
Filings indexed 696 across all filing types
Latest filing 2026-02-07 Regulatory Filings
Country IN India
Listing BSE.NS GUJTHEM

About Gujarat Themis Biosyn Ltd.

https://www.gtbl.in

Gujarat Themis Biosyn Ltd. specializes in the manufacture of active pharmaceutical ingredients and intermediates through advanced fermentation technology. The company focuses on the production of fermentation-based bulk drugs, with a primary product portfolio that includes Rifampicin intermediates and Lovastatin. Utilizing large-scale fermentation processes, the organization engages in strain improvement and media optimization to enhance yield and efficiency. The company operates a dedicated manufacturing facility equipped for complex biotechnological processes. Through technical collaborations with international entities, it has integrated specialized expertise in fermentation science to support the development of high-purity chemical compounds. Its operations are centered on providing essential building blocks for various therapeutic applications, maintaining a focus on technical precision and process-driven manufacturing excellence.

Recent filings

Filing Released Lang Actions
Please refer to the attachment.
Regulatory Filings
2026-02-07 English
Please refer to the attachment.
Regulatory Filings
2026-02-07 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the newspaper publication of unaudited financial results for the quarter and nine months ended 31st December 2025. It references compliance with SEBI regulations and encloses copies of the newspaper publication of these financial results. The document is a notification or announcement of the publication of financial results rather than the full financial report itself. The length is about 15,000 characters, but the content is primarily an announcement of the publication of the unaudited financial results, not the detailed report or financial statements. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Regulatory Filing (RNS) because it is an announcement of the publication of financial results, not the results themselves or a detailed interim report.
2026-02-06 English
Please refer to the attachment
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the newspaper publication of unaudited financial results for the quarter and nine months ended 31st December 2025. It references compliance with SEBI regulations and encloses copies of the newspaper publication of these financial results. The document is essentially an announcement informing the exchanges about the publication of the unaudited quarterly financial results. It does not contain the full financial statements or detailed financial analysis itself, but rather serves as a notification of the publication of such results in newspapers. According to the classification rules, such a document is an announcement of a report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and announcements that do not fit other specific categories. The document length (15,000 characters) is sufficient but the content is clearly an announcement, not the full interim or quarterly report.
2026-02-06 English
Outcome of Board Meeting
Regulatory Filings
2026-02-05 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Q3 & 9M FY2025-26' and contains detailed financial highlights for the third quarter and nine months of fiscal year 2025-26, including revenue, EBITDA, PAT, EPS, balance sheet highlights, and management commentary. It is addressed to stock exchanges and references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosures including investor presentations. The document is approximately 15,000 characters long and contains substantive financial data and analysis, not merely an announcement or a link to a report. The content is consistent with an investor presentation focusing on business overview, financial performance, and strategic updates. Therefore, the document fits the category of an Investor Presentation (IP).
2026-02-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.